colorect
cancer
crc
major
contributor
cancer
mortal
morbid
develop
develop
countri
world
fourth
deadliest
cancer
lung
liver
stomach
cancer
account
almost
death
epiderm
growth
factor
receptor
egfr
member
erythroblast
leukemia
viral
oncogen
homologhuman
epiderm
growth
factor
receptor
erbbher
famili
receptor
tyrosin
kinas
rtk
one
promin
therapeut
target
metastat
crc
mcrc
egfr
commonli
overexpress
cell
membran
sever
cancer
includ
lung
colon
head
neck
esophag
cancer
ligand
bind
caus
homo
heterodimer
egfr
famili
member
kinaseinact
result
downstream
activ
protein
kinas
kinas
mek
phosphatidylinositol
pathway
eventu
acceler
cell
growth
carcinogenesi
accordingli
numer
target
molecul
develop
either
block
ligand
bind
inhibit
egfr
tyrosin
kinas
activ
antiegfr
therapi
base
block
ligand
bind
monoclon
antibodi
mab
wide
use
clinic
practic
egfrexpress
cancer
develop
antiegfr
mab
mileston
mcrc
treatment
us
food
drug
administr
approv
cetuximab
chimer
mab
treatment
patient
irinotecanrefractori
andor
oxaliplatinrefractori
mcrc
howev
cetuximab
therapi
modest
impact
mcrc
achiev
approxim
object
respons
rate
use
monotherapi
chemorefractori
mcrc
key
reason
limit
success
cetuximab
mcrc
includ
sever
primari
de
novo
secondari
acquir
resist
egfrtarget
therapi
rapidli
accumul
bodi
evid
indic
resist
egfr
blockad
mcrc
parallel
downstream
egfr
mutat
ra
exon
braf
exon
exon
amplif
gene
kra
met
howev
predict
respons
antiegfr
mab
patient
mcrc
remain
challeng
extens
research
determin
even
patient
tumor
harbor
wildtyp
kra
nra
braf
interindividu
variabl
respons
cetuximab
exist
larg
proport
respons
patient
acquir
resist
cetuximab
emerg
despit
absenc
detect
mutat
ra
braf
clinic
practic
identifi
specif
easili
assay
secret
biomark
antiegfr
mab
paramount
import
predict
monitor
therapeut
respons
resist
although
ra
braf
identifi
predict
prognost
biomark
patient
mcrc
treat
antiegfr
mab
due
unmet
clinic
need
hypothes
addit
biomark
may
also
contribut
antiegfr
antibodi
efficaci
demonstr
possibl
use
prss
serin
proteas
predict
marker
mcrc
respons
cetuximab
treatment
encod
pancreat
serin
proteinas
also
name
major
pancreat
digest
enzym
also
catalyz
activ
pancreat
zymogen
activ
enzym
normal
occur
intestin
heterozyg
pathogen
variant
identifi
confirm
diagnosi
hereditari
pancreat
inform
treatment
enabl
variantspecif
test
atrisk
famili
member
express
varieti
cancer
cell
line
tissu
tumorassoci
trypsinogen
also
strongli
associ
depth
invas
lymph
node
metastasi
advanc
patholog
tumornodemetastasi
stage
recurr
ovarian
cancer
esophag
squamou
cell
carcinoma
crc
studi
show
express
level
highli
correl
sensit
colon
cancer
cell
cetuximab
respons
patient
mcrc
cetuximab
therapi
detail
mechanist
analysi
indic
prss
cleav
cetuximab
mab
includ
bevacizumab
trastuzumab
lead
antibodi
resist
cetuximab
bevacizumab
combin
serin
peptidas
inhibitor
kazal
type
prss
inhibitor
inhibit
cell
growth
effici
cetuximab
bevacizumab
alon
xenograft
model
also
identifi
preliminarili
valid
signific
associ
serum
level
patient
mcrc
lack
respons
cetuximab
therapi
prss
level
serum
healthi
individu
patient
mcrc
analyz
poor
efficaci
antibodi
therapi
observ
patient
aberr
prss
express
use
systemat
character
clinic
data
patient
mcrc
subdivid
patient
two
major
subgroup
accord
serum
level
found
signific
differ
progressionfre
surviv
pf
valid
find
use
cancer
genom
atla
tcga
databas
examin
whether
clinic
outcom
patient
receiv
antibodi
monotherapi
associ
prss
express
consist
result
patient
treat
cetuximab
found
patient
low
express
longer
pf
high
express
togeth
find
indic
prss
play
essenti
role
develop
cetuximab
resist
patient
mcrc
may
candid
biomark
respons
mab
cetuximab
bevacizumab
trastuzumab
particular
also
presum
combin
prss
inhibitor
mab
may
viabl
option
cancer
patient
rel
high
prss
level
download
analyz
compar
wholegenom
express
profil
establish
affymetrix
microarray
via
broad
institut
wwwbroadinstituteorgcgibincancerdatasetscgi
found
wide
literatur
search
cell
line
databas
either
cetuximab
resist
cetuximab
sensit
systemat
comparison
gene
express
data
cell
line
determin
express
prss
famili
gene
includ
higher
cetuximabresist
cell
line
cetuximabsensit
cell
line
fig
tabl
accordingli
hypothes
prss
gene
may
contribut
cetuximab
resist
investig
impact
cetuximab
efficaci
compar
express
data
follow
six
colon
cancer
cell
line
difi
lovo
cell
line
express
egfr
fig
cetuximab
inhibit
prolifer
surviv
vari
degre
fig
consist
previou
find
cell
growth
assay
show
difi
cell
cetuximab
sensit
lovo
cell
moder
cetuximab
sensit
cell
cetuximab
resist
examin
mrna
express
cell
line
revers
transcript
pcr
show
significantli
highli
express
cetuximabresist
cell
line
cetuximabsensit
cell
line
fig
express
level
show
almost
differ
cetuximabresist
cetuximabsensit
cell
line
next
assess
express
extracellular
secret
protein
cell
line
anticip
significantli
highli
express
cetuximabresist
cell
line
cetuximabsensit
cell
line
fig
b
confirm
mrna
level
quantit
pcr
qpcr
fig
protein
level
immunoblot
fig
enzymelink
immunosorb
assay
elisa
use
antibodi
fig
furthermor
immunohistochem
ihc
analysi
show
express
tumor
sampl
cetuximabresist
patient
mcrc
higher
sampl
cetuximabsensit
patient
mcrc
fig
result
suggest
cetuximab
resist
relat
confirm
role
cetuximab
resist
stabl
cell
lovo
cell
gener
use
lentivirusbas
short
hairpin
rna
shrna
approach
knockdown
effici
shrna
five
batch
pool
cell
compar
nontarget
control
cell
pool
cell
demonstr
knockdown
mrna
level
shown
qpcr
fig
rtpcr
fig
secret
protein
level
shown
elisa
use
antibodi
fig
cell
also
term
cell
respect
pool
lovo
cell
demonstr
knockdown
mrna
express
shown
qpcr
fig
knockdown
secret
protein
level
fig
next
confirm
respons
lovo
cell
cetuximab
perform
mtt
bromid
assay
use
pool
show
maximum
express
knockdown
control
cell
cetuximab
treatment
compar
control
cell
express
knockdown
cell
line
exhibit
significantli
decreas
prolifer
fig
h
test
whether
aberrantli
upregul
express
suffici
drive
cellular
resist
cetuximab
overexpress
matur
peptid
fulllength
peptid
difi
cell
lovo
cell
qpcr
analysi
show
overexpress
difi
cell
fig
lovo
cell
fig
elisa
analysi
show
secret
overexpress
difi
cell
fig
lovo
cell
fig
overexpress
significantli
increas
cellular
resist
cetuximab
suggest
increas
express
correl
wors
respons
cetuximab
colon
cancer
cell
line
fig
l
addit
explor
import
prss
cetuximab
resist
assess
influenc
knockdown
overexpress
cellular
prolifer
cell
line
found
differ
growth
origin
cell
line
knockdown
cell
line
fig
overexpress
cell
line
fig
use
supernat
lovo
difi
cell
cultur
difi
cell
found
cell
enhanc
express
prss
paracrin
effect
reduc
sensit
neighbor
cell
produc
less
prss
cetuximab
indic
prss
contribut
cetuximab
resist
fig
j
k
togeth
result
show
express
downregul
confer
cetuximab
sensit
convers
express
upregul
correl
wors
respons
cetuximab
colon
cancer
skin
cell
line
indic
may
contribut
cetuximab
resist
mcrc
mekextracellular
kinas
mekerk
signal
pathway
downstream
pathway
egfr
activ
egfr
ligand
bind
extracellular
domain
egfr
drive
cell
prolifer
surviv
invas
cetuximab
act
block
ligand
bind
egfr
extracellular
domain
therebi
prevent
ligandmedi
egfr
signal
inhibit
increas
phosphoryl
erk
perk
phosphoryl
akt
pakt
level
fig
henc
elucid
role
cetuximab
resist
perform
immunoblot
phosphoryl
egfr
pegfr
perk
pakt
stabl
express
knockdown
lovo
cell
cell
pegfr
perk
pakt
level
increas
cell
compar
shscrm
scrambl
cell
fig
b
next
examin
whether
exogen
addit
medium
colon
cancer
cell
would
decreas
cetuximabmedi
inhibit
mekerk
signal
anticip
ectop
express
difi
lovo
cell
decreas
cetuximabmedi
inhibit
pegfr
perk
pakt
fig
c
conclus
express
knockdown
increas
cetuximabmedi
inhibit
mekerk
convers
ectop
express
decreas
inhibit
mechan
caus
cetuximab
resist
involv
decreas
efficaci
cetuximab
serin
proteinas
consid
whether
caus
cellular
resist
cetuximab
cleav
cetuximab
use
recombin
human
cultur
supernat
colon
cancer
cell
resolv
question
recombin
human
cell
cultur
supernat
cleav
cetuximab
fig
also
note
colon
cancer
cell
cultur
supernat
recombin
human
pattern
cetuximab
cleavag
indic
cell
cultur
supernat
cleav
mab
fig
trypsin
protein
homolog
consid
whether
residu
trypsin
cell
cultur
supernat
cleav
cetuximab
cell
underw
trypsin
digest
accordingli
use
elisa
detect
level
cell
cultur
supernat
level
cell
cultur
supernat
hour
low
detect
increas
time
fig
suggest
express
cell
cultur
supernat
residu
trypsin
cleav
cetuximab
result
show
band
cleavag
produc
may
effect
also
captur
goat
antihuman
immunoglobulin
g
igg
fig
doubt
tradit
elisa
involv
use
horseradish
peroxidas
hrp
rabbit
goat
antihuman
igg
detect
antibodi
could
thoroughli
uncov
pharmacokinet
profil
cetuximab
patient
solid
tumor
express
egfr
test
pharmacokinet
profil
cetuximab
use
goat
antimous
igg
antibodi
captur
heavi
light
chain
cetuximab
goat
antihuman
igg
antibodi
detect
antibodi
immunoblot
show
use
goat
antimous
igg
antibodi
detect
antibodi
yield
accur
pharmacokinet
profil
cetuximab
fig
b
c
detail
cell
cultur
supernat
produc
highest
degre
cetuximab
cleavag
follow
supernat
moder
cetuximabsensit
lovo
cell
wherea
degre
cleavag
produc
cell
cultur
supernat
cetuximabsensit
difi
cell
lowest
fig
b
c
also
test
cetuximab
cleavag
use
cell
cultur
supernat
mock
control
cell
lovo
cell
cetuximab
cleavag
significantli
decreas
express
knockdown
cell
line
compar
mock
control
cell
fig
g
fig
also
assess
cetuximab
cleavag
use
cell
cultur
supernat
mock
control
difi
cell
lovo
cell
convers
exogen
addit
medium
cell
increas
cetuximab
cleavag
fig
h
k
fig
e
f
proteolyt
cleavag
pattern
cetuximab
cell
cultur
supernat
cell
cell
prove
cell
cultur
supernat
cleav
cetuximab
confirm
decreas
cetuximab
efficaci
eventu
lead
cetuximab
resist
detect
level
pharmacokinet
profil
cetuximab
serum
two
patient
mcrc
one
patient
respons
cetuximab
resist
cetuximab
elisa
show
significantli
lower
level
patient
good
respons
patient
fig
immunoblot
show
lower
degre
cetuximab
cleavag
patient
good
respons
patient
fig
next
detect
pharmacokinet
cetuximab
two
patient
use
goat
antimous
igg
antibodi
found
much
lower
cetuximab
cleavag
speed
patient
good
respons
patient
fig
demonstr
caus
resist
mab
cleav
mab
data
show
cultur
supernat
colon
cancer
cell
recombin
human
cleav
mab
fig
k
identifi
cleavag
site
analyz
ntermin
partial
sequenc
cleav
heavi
chain
use
edman
cleavag
procedur
fig
ntermin
sequenc
cleav
heavi
chain
thrvalseralaalaserthrlysglyproservalpheproleu
fig
cleavag
occur
fig
cleavag
site
never
report
cleavag
site
variabl
heavi
chain
region
constant
heavi
chain
region
heavi
chain
found
cetuximab
also
multitud
mab
includ
bevacizumab
trastuzumab
fig
cultur
supernat
colon
cancer
cell
recombin
human
also
cleav
bevacizumab
trastuzumab
fig
e
almost
ident
cleavag
pattern
indic
secret
cancer
cell
cleav
mab
nevertheless
neither
cultur
supernat
colon
cancer
cell
recombin
human
could
cleav
aflibercept
potenti
cleavag
site
fig
result
suggest
cultur
supernat
colon
cancer
cell
cleav
rang
mab
harbor
potenti
cleavag
site
includ
cetuximab
bevacizumab
trastuzumab
fig
e
decreas
respons
mab
ultim
caus
resist
find
suggest
may
caus
cetuximab
resist
cleav
cetuximab
increasingli
greater
degre
although
cultur
supernat
colon
cancer
cell
could
cleav
cetuximab
bevacizumab
trastuzumab
cleavag
pattern
cetuximab
differ
complet
human
mab
bevacizumab
trastuzumab
almost
ident
pattern
cleavag
fig
potenti
cleavag
region
cetuximab
differ
cleavag
region
bevacizumab
trastuzumab
one
amino
acid
alanin
cetuximab
serin
bevacizumab
trastuzumab
fig
therefor
hypothes
cleavag
mab
may
sequenc
specif
consid
whether
mutat
amino
acid
potenti
cleavag
region
could
prevent
cleavag
mab
clarifi
sequenc
specif
zdock
algorithm
builtin
modul
accelri
discoveri
studio
use
simul
dock
cetuximab
whose
conform
deriv
crystal
structur
respect
design
purifi
mutant
cetuximab
mab
mutat
cleavag
region
contain
potenti
recognit
region
contain
base
structur
model
comput
design
fig
cleavag
mutant
mab
contain
lower
cetuximab
cleavag
mutant
mab
contain
greater
cetuximab
fig
c
howev
cleavag
mutant
mab
contain
almost
ident
cetuximab
fig
e
f
soybean
trypsin
inhibitor
type
sbti
sigmaaldrich
catalog
urinari
trypsin
inhibitor
ulinastatin
also
known
pancreat
secretori
trypsin
inhibitor
tumorassoci
trypsin
inhibitor
tati
suppress
trypsin
activ
consid
whether
agent
could
inhibit
proteolyt
cleavag
mab
sbti
ulinastatin
recombin
human
suppress
proteolyt
cleavag
bevacizumab
recombin
phosphatebuff
salin
pb
strongest
inhibitor
ulinastatin
weakest
fig
b
also
test
inhibitori
effect
sbti
proteolyt
cleavag
cetuximab
high
concentr
cell
cultur
supernat
immunoblot
show
sbti
bare
suppress
cleavag
cetuximab
cell
cultur
supernat
fig
b
overexpress
multipl
human
cancer
increas
serum
level
correl
aggress
diseas
assess
express
colon
cancer
cell
line
express
highest
cell
fig
c
fig
may
cetuximab
cleavag
cell
cultur
supernat
weak
although
express
highest
cell
line
among
colon
cancer
cell
line
fig
c
fig
e
next
construct
prokaryot
express
vector
contain
success
purifi
protein
fig
detect
activ
immunoblot
perform
use
purifi
confirm
inhibit
reduc
proteolyt
cleavag
observ
purifi
group
compar
group
purifi
significantli
inhibit
proteolyt
cleavag
mab
vitro
cell
cultur
supernat
fig
e
g
result
suggest
may
effect
inhibitor
proteolyt
cleavag
cetuximab
result
describ
previou
studi
other
show
effici
trypsin
inhibitor
partial
inhibit
proteolyt
cleavag
mab
hypothes
combin
treatment
purifi
cetuximab
bevacizumab
may
lead
supraaddit
reduct
colon
cancer
cell
growth
accordingli
test
effect
ngml
cetuximab
cell
prolifer
expect
cetuximab
significantli
decreas
cell
viabil
fig
consist
previou
report
purifi
also
significantli
increas
cell
prolifer
fig
basi
compel
vitro
evid
next
assess
therapeut
efficaci
combin
cetuximab
treatment
lovo
cell
xenograft
model
treatment
via
cetuximab
inject
day
significantli
suppress
tumor
growth
fig
compar
either
cetuximab
alon
cetuximab
combin
exhibit
clear
synergist
effect
fig
furthermor
combin
treatment
cetuximab
result
greater
reduct
tumor
weight
either
cetuximab
treatment
alon
fig
determin
whether
differ
egfrmek
signal
exist
cetuximab
treatment
alon
combin
treatment
vivo
measur
perk
stain
xenograft
tumor
section
xenograft
perk
level
significantli
decreas
follow
treatment
cetuximab
alon
combin
cetuximab
fig
fig
moreov
cetuximab
result
greater
reduct
xenograft
perk
level
cetuximab
alon
fig
fig
confirm
vitro
result
indic
combin
cetuximab
treatment
led
supraaddit
reduct
lovo
tumor
growth
perform
similar
xenograft
studi
use
cell
expect
inhibit
tumor
growth
either
cetuximab
bevacizumab
alon
mice
fig
similar
observ
lovo
mice
fig
mice
treat
cetuximab
significantli
decreas
perk
level
treat
either
cetuximab
alon
fig
also
assess
microvascular
format
xenograft
tumor
section
via
stain
endomucin
immunofluoresc
ihc
show
significantli
decreas
microvascular
format
mice
treat
bevacizumab
mice
treat
either
bevacizumab
alon
fig
fig
use
determin
microvascular
densiti
basi
express
select
five
highmagnif
field
view
count
number
cell
express
local
microvascular
endotheli
cell
xenograft
tumor
section
statist
signific
decreas
number
capillari
distribut
microcircul
note
xenograft
tumor
treat
bevacizumab
compar
treat
either
bevacizumab
alon
fig
fig
consist
previou
report
also
found
induc
cancer
cell
prolifer
fig
b
e
observ
support
premis
effect
inhibit
proteolyt
cleavag
mab
improv
cur
effect
mab
cetuximab
mainli
extens
use
treat
patient
mcrc
use
elisa
examin
level
serum
healthi
individu
n
patient
mcrc
n
determin
clinic
signific
level
mcrc
fig
data
file
serum
level
patient
averag
ngml
significantli
higher
healthi
individu
averag
ngml
fig
patient
receiv
cetuximab
monotherapi
fig
data
file
serum
level
patient
primari
cetuximab
resist
n
averag
ngml
significantli
higher
cetuximabrespons
patient
n
averag
ngml
fig
also
found
patient
serum
level
cetuximab
treatment
significantli
higher
cetuximab
treatment
diseas
progress
fig
data
file
howev
differ
observ
respond
nonrespond
treat
chemotherapi
alon
fig
data
file
differ
observ
level
chemotherapi
level
chemotherapi
fig
data
file
basi
whether
level
exceed
averag
level
patient
divid
patient
receiv
cetuximab
monotherapi
two
group
high
low
express
group
kaplanmei
curv
patient
consist
demonstr
much
wors
overal
surviv
os
patient
high
patient
low
median
surviv
day
versu
day
respect
p
fig
indic
high
level
clearli
relat
poor
cetuximab
respons
mcrc
conduct
analys
determin
whether
prognost
impact
express
independ
clinic
variabl
pool
patient
receiv
cetuximab
monotherapi
avail
pf
data
n
univari
multivari
analys
factor
affect
pf
tabl
multivari
analysi
show
effect
express
pf
independ
clinic
variabl
tabl
confirm
high
level
clearli
relat
poor
respons
mab
includ
cetuximab
bevacizumab
differ
cancer
analyz
tcga
databas
patient
cancer
receiv
antibodi
monotherapi
express
low
head
neck
squamou
cell
carcinoma
hnscc
tissu
divid
patient
hnscc
receiv
cetuximab
monotherapi
n
high
express
n
low
express
group
n
base
median
level
hnscc
tissu
sampl
tcga
databas
expect
patient
low
express
significantli
longer
pf
patient
high
express
median
surviv
day
versu
day
respect
p
fig
furthermor
determin
whether
prss
express
affect
prognosi
patient
cancer
consist
previou
studi
found
signific
differ
os
high
group
fig
also
divid
patient
colorect
adenocarcinoma
receiv
bevacizumab
monotherapi
n
high
low
express
group
patient
whose
level
exceed
median
level
patient
colorect
carcinoma
assign
group
n
remain
patient
assign
group
n
similar
result
patient
hnscc
patient
colorect
carcinoma
low
express
significantli
longer
pf
patient
high
express
median
surviv
day
versu
day
respect
p
fig
fig
also
divid
patient
glioma
receiv
bevacizumab
monotherapi
n
two
group
use
method
use
patient
hnscc
consist
result
patient
hnscc
colorect
carcinoma
patient
glioma
low
express
longer
pf
patient
high
express
median
surviv
day
versu
day
respect
p
fig
c
express
data
normal
patient
ovarian
serou
cystadenocarcinoma
consequ
divid
patient
receiv
bevacizumab
monotherapi
n
express
group
express
less
zero
n
express
group
express
zero
n
kaplanmei
analysi
patient
consist
demonstr
much
wors
surviv
durat
patient
patient
median
surviv
day
versu
day
respect
p
fig
e
f
togeth
find
suggest
high
prss
express
level
associ
poor
respons
mab
treatment
assess
whether
experiment
find
regard
relev
patient
mcrc
clinic
practic
use
elisa
immunoblot
analys
examin
whether
level
use
determin
mab
respons
perform
clinic
valid
use
elisa
measur
serum
level
patient
mcrc
receiv
cetuximab
treatment
data
file
collect
serum
sampl
patient
treatment
everi
week
treatment
patient
categor
partial
respons
stabl
diseas
progress
diseas
pd
radiolog
assess
accord
respons
evalu
criteria
solid
tumor
recist
among
patient
mcrc
receiv
cetuximab
monotherapi
patient
longitudin
serum
sampl
eventu
develop
pd
data
file
compar
chang
patient
level
antibodi
monotherapi
imag
result
found
level
gradual
increas
reach
high
level
pd
occur
fig
data
file
specif
compar
tumor
marker
carcinoembryon
antigen
cea
carbohydr
antigen
circul
level
patient
better
correl
treatment
outcom
reach
nadir
best
respons
cetuximab
obtain
level
increas
tumor
progress
determin
computer
tomographi
ct
nine
patient
level
treatment
appear
associ
treatment
outcom
postul
patient
may
hyperactiv
egfr
pathway
downstream
receptor
hyperactiv
relat
pathway
would
uncoupl
secret
respons
cetuximab
treatment
togeth
find
indic
serum
level
correl
treatment
outcom
accord
standard
radiolog
assess
target
mab
includ
cetuximab
bevacizumab
effect
prolong
surviv
patient
cancer
becom
standard
compon
therapi
patient
mcrc
nevertheless
major
obstacl
antibodi
therapi
includ
lack
secret
respons
biomark
primarysecondari
resist
mab
previou
data
shown
mcrc
lesion
harbor
kra
braf
mutat
highli
associ
poor
prognosi
poor
object
respons
cetuximab
therapi
therefor
investig
mechan
mab
resist
identif
use
biomark
mab
therapi
may
guid
treatment
select
signific
clinic
impact
greatli
warrant
present
work
aim
character
prss
secret
involv
respons
resist
cetuximab
therapi
exploit
prss
biomark
discoveri
work
shed
new
light
influenc
prss
cancer
essenti
role
prss
mab
resist
although
recent
studi
also
demonstr
tissu
express
trypsinogen
correl
significantli
tumor
aggress
recurr
poor
prognosi
crc
analysi
reveal
level
close
associ
cetuximab
resist
mcrc
prss
produc
secret
cancer
cell
also
mediat
prourokinas
metalloproteinas
activ
thu
promotingfacilit
angiogenesi
tumor
invas
digest
compon
extracellular
matrix
present
find
rais
possibl
crucial
determin
resist
cetuximab
therapi
mcrc
first
found
significantli
higher
express
cetuximabresist
cell
cetuximabsensit
cell
second
exogen
addit
medium
human
colon
cancer
cell
difi
lovo
cell
increas
cetuximab
resist
convers
silenc
lovo
cell
confer
cetuximab
sensit
third
recombin
cell
cultur
supernat
test
colon
cancer
cell
line
cleav
cetuximab
manner
furthermor
thorough
cleavag
observ
supernat
cell
resist
cetuximab
fourth
express
knockdown
increas
cetuximabmedi
inhibit
pegfr
pakt
perk
ectop
express
decreas
inhibit
therefor
mechanist
demonstr
cleav
mab
ie
cetuximab
bevacizumab
trastuzumab
thu
decreas
respons
antibodi
ultim
caus
antibodi
resist
togeth
find
suggest
prss
may
lead
antibodi
resist
cleav
antibodi
eventu
decreas
efficaci
convent
cleavag
site
lie
lysin
arginin
residu
cleavag
site
valin
threonin
mab
never
report
also
found
cleavag
mab
sequenc
specif
modifi
amino
acid
decreas
degre
mutant
mab
cleavag
fig
c
may
theoret
basi
mab
modif
protect
pancrea
autodigest
prevent
activ
pancreat
proteas
unlik
inhibitor
name
sbti
ulinastatin
significantli
suppress
cleavag
cetuximab
bevacizumab
vivo
vitro
result
show
cetuximab
bevacizumab
addit
effect
inhibit
lovo
cell
prolifer
find
consist
result
report
show
combin
mab
egfr
led
supraaddit
reduct
growth
invas
cell
furthermor
concomit
tumor
express
egfr
associ
better
prognosi
crc
indic
antiegfr
mab
may
produc
better
respons
crc
cell
support
find
data
also
reveal
administ
antiegfr
mab
cetuximab
bevacizumab
mice
bear
xenograft
attenu
tumor
growth
respect
approxim
respect
combin
moreov
administ
cetuximab
mice
bear
lovo
xenograft
attenu
tumor
growth
approxim
combin
fig
b
administ
alon
mice
bear
lovo
xenograft
promot
tumor
growth
fig
b
consist
previou
studi
report
extracellular
promot
cell
prolifer
downregul
metallothionein
express
interact
egfr
activ
downstream
signal
structur
similar
egf
togeth
find
indic
function
signific
cetuximab
resist
warrant
investig
identifi
effect
inhibitor
therapi
patient
mcrc
specif
blockad
may
viabl
option
patient
mcrc
highserum
level
resist
antiegfr
therapi
prognost
perspect
aberr
express
correl
significantli
cetuximab
respons
rate
patient
mcrc
found
patient
better
cetuximab
respons
significantli
lower
serum
level
patient
cetuximab
resist
speed
cetuximab
cleavag
also
much
slower
patient
good
respons
patient
wors
respons
cetuximab
treatment
demonstr
may
caus
mab
resist
also
found
serum
level
increas
cetuximab
administr
verifi
antiegfr
drug
induc
secret
event
specif
drug
respons
resist
furthermor
elisa
show
patient
mcrc
significantli
higher
serum
level
healthi
individu
fig
patient
cetuximab
resist
significantli
higher
serum
level
cetuximabrespons
patient
fig
kaplanmei
curv
consist
demonstr
much
wors
surviv
patient
high
express
patient
low
express
fig
indic
level
clearli
relat
poor
respons
cetuximab
mcrc
analys
patient
cancer
receiv
antibodi
monotherapi
reveal
patient
low
express
longer
pf
patient
high
express
regardless
whether
patient
hnscc
fig
colorect
adenocarcinoma
fig
glioma
fig
ovarian
serou
cystadenocarcinoma
fig
among
patient
signific
differ
os
note
express
group
fig
b
f
togeth
find
indic
high
prss
express
level
associ
poor
respons
mab
treatment
poor
overal
cancer
prognosi
last
preliminari
valid
find
serum
patient
mcrc
suggest
level
secret
correl
respons
cetuximab
treatment
fig
data
file
indic
may
better
predict
marker
cetuximab
respons
tumor
marker
cea
although
work
need
assess
full
potenti
biomark
work
suggest
serum
express
level
drug
resist
profil
correl
well
xenograft
mcrc
patient
characterist
illustr
molecular
connect
intracellular
extracellular
signal
potenti
relev
cancer
diagnost
therapeut
patient
serum
level
correl
treatment
outcom
evalu
standard
radiolog
assess
may
help
identifi
patient
mcrc
poor
prognos
andor
cetuximab
resist
level
may
therefor
serv
noninvas
predict
marker
cetuximab
respons
accord
find
prss
detect
develop
tailor
manag
crc
also
diseas
treat
mab
preliminari
valid
find
serum
patient
mcrc
suggest
secret
level
correl
respons
cetuximab
treatment
knowledg
first
studi
suggest
serum
express
level
use
prognost
biomark
crc
potenti
predict
biomark
patient
mcrc
receiv
cetuximab
treatment
conclus
find
provid
rational
develop
inhibitor
mab
treatment
cancer
diseas
altern
mab
modif
target
cleavag
site
may
increas
respons
mab
benefit
patient
work
may
facilit
noninvas
monitor
cetuximab
treatment
patient
mcrc
although
larg
blind
independ
studi
need
determin
true
clinic
potenti
difi
cell
cultur
medium
hyclon
supplement
vv
fetal
bovin
serum
fb
hyclon
lovo
cell
routin
cultur
rpmi
medium
hyclon
supplement
vv
fb
cell
human
embryon
kidney
hek
cell
cultur
highglucos
medium
hyclon
contain
vv
fb
cell
cultur
gener
stabl
cell
line
human
express
construct
encod
fulllength
fusion
protein
matur
fusion
protein
gener
clone
pcramplifi
sequenc
pmscupuro
amersham
pharmacia
biotech
lipofectamin
invitrogen
use
transfect
two
day
transfect
stabl
overexpress
cell
line
select
puromycin
day
pool
clone
singl
clone
screen
qpcr
standard
immunoblot
elisa
induc
encod
sequenc
lentivir
prepar
infect
perform
cell
transduc
shrna
grown
medium
supplement
fb
presenc
puromycin
crc
cell
line
plate
sixwel
plate
hour
cell
wash
pb
cultur
hour
serumfre
medium
cell
supernat
protein
collect
immunoblot
also
detect
biochem
respons
cetuximabtr
cell
immunoblot
incub
serumfre
medium
cell
treat
cetuximab
hour
cell
extract
freshli
prepar
analyz
antibodi
egfr
pakt
akt
mapk
mapk
dehydrogenas
gapdh
purchas
cell
signal
technolog
phosphorylationspecif
egfr
antibodi
antibodi
obtain
abcam
serum
trypsin
test
use
elisa
kit
human
trypsin
pan
specif
duoset
elisa
kit
r
system
accord
manufactur
protocol
total
rna
extract
reversetranscrib
goscript
revers
transcript
system
realtim
pcr
perform
use
quantitect
sybr
green
pcr
master
mix
appli
biosystem
triplic
analyz
abi
fast
realtim
pcr
system
appli
biosystem
human
gapdh
mrna
level
quantifi
revers
transcript
pcr
rtpcr
realtim
qpcr
primer
sequenc
follow
forward
revers
primer
sequenc
follow
forward
revers
gapdh
primer
sequenc
follow
forward
revers
determin
cetuximab
sensit
cell
seed
ml
medium
cell
per
well
plastic
cultur
plate
serial
dilut
cetuximab
serumfre
medium
ad
cell
well
contain
medium
use
control
cell
treat
cetuximab
plate
incub
hour
cell
viabil
assess
cell
count
viabl
cell
detect
hour
treatment
use
measur
absorb
nm
rel
rate
cell
growth
cell
line
factor
analysi
subtract
absorb
time
valu
control
treatment
group
experi
replic
minimum
three
time
mab
cleavag
recombin
human
recombin
mab
combin
ml
pb
incub
humidifi
atmospher
recombin
intermixtur
collect
hour
mab
cleavag
crc
ml
serumfre
medium
harbor
mab
ad
cultur
plate
contain
cell
incub
humidifi
atmospher
supernat
collect
hour
also
collect
cell
cultur
supernat
crc
cell
cultur
hour
without
serum
ad
mab
supernat
incub
mixtur
humidifi
atmospher
hour
pharmacokinet
analysi
cetuximab
ml
blood
collect
cetuximab
administr
hour
infus
first
start
blood
sampl
allow
clot
min
room
temperatur
centrifug
min
serum
supernat
transfer
label
corn
cryotub
store
upright
serum
cell
cultur
supernat
cetuximab
concentr
detect
use
valid
sandwich
elisa
briefli
egfrcoat
polystyren
microtit
plate
load
serum
sampl
wash
incub
hrpconjug
goat
antihuman
igg
sigmaaldrich
hrpconjug
goat
antimous
igg
pierc
elut
unbound
conjug
chromogen
substrat
ad
color
reaction
product
measur
use
microtit
plate
reader
nm
calibr
curv
linear
concentr
rang
pharmacokinet
variabl
calcul
data
assay
specif
linear
precis
accuraci
limit
quantif
obtain
vivo
experi
suspens
cell
cell
per
mous
lovo
cell
cell
per
mous
inject
subcutan
left
flank
femal
nude
mice
n
per
group
anim
maintain
laminar
air
flow
unit
asept
condit
experi
perform
accord
relev
local
institut
guidelin
tumor
format
monitor
everi
day
use
calip
tumor
volum
calcul
use
modifi
ellipsoid
formula
length
rtk
exert
domin
control
signal
human
kra
mutant
crc
mean
tumor
volum
approxim
mice
randomli
assign
treatment
vehicl
normal
salin
cetuximab
mg
per
mous
normal
salin
per
mous
bevacizumab
mgkg
normal
salin
drug
combin
cetuximab
bevacizumab
compound
administ
dose
schedul
singl
agent
mice
receiv
drug
normal
salin
intraperiton
inject
everi
day
day
bodi
weight
gener
condit
mice
measur
everi
day
mice
euthan
tumor
volum
tumor
becom
excess
ulcer
accord
nation
guidelin
tumor
tissu
collect
immunoblot
formalinfix
paraffinembed
ihc
studi
statist
signific
analyz
use
unpair
twotail
student
test
sampl
contain
least
protein
ml
pb
separ
gel
electrophoresi
gel
subsequ
incub
stain
buffer
room
temperatur
overnight
decolor
buffer
acet
acid
use
wash
gel
human
code
region
pcramplifi
human
mammari
retrovir
complementari
dna
librari
clone
prokaryot
express
vector
primer
use
follow
forward
revers
fusion
protein
express
escherichia
coli
purifi
nickel
affin
size
exclus
chromatographi
mmliter
induct
hour
estim
optim
express
strategi
express
fusion
protein
detect
western
blot
coomassi
brilliant
blue
stain
mice
euthan
tumor
excis
fix
formalin
embed
paraffin
cut
section
dewax
hydrat
stain
hematoxylin
eosin
use
standard
techniqu
ihc
stain
procedur
follow
tissu
section
incub
min
room
temperatur
hydrogen
peroxid
block
endogen
peroxidas
slide
block
incub
follow
primari
antibodi
antiegfr
nichirei
bioscienc
pegfr
cell
signal
technolog
perk
cell
signal
technolog
pakt
cell
signal
technolog
endomucin
ebiosci
abcam
slide
subsequ
incub
polymerhrp
antirabbit
dako
antimous
dako
secondari
antibodi
tissu
stain
visual
use
dapi
slide
counterstain
hematoxylin
dehydr
mount
coimmunofluoresc
stain
procedur
isolectin
invitrogen
follow
preprocess
ihc
stain
describ
slide
incub
primari
antibodi
isolectin
subsequ
incub
appropri
fluorescenceconjug
secondari
antibodi
dapi
counterstain
use
identifi
nuclei
prospect
singlecent
studi
monitor
dynam
tumorrel
level
mcrc
progress
patient
serum
local
ethic
committe
affili
hospit
academi
militari
medic
scienc
beij
china
approv
studi
protocol
inform
consent
obtain
patient
tissu
acquisit
handl
human
tissu
specimen
carri
accord
institut
state
regul
guidelin
tumor
biopsi
longitudin
serum
sampl
ml
collect
patient
baselin
everi
week
therapi
pd
identifi
serum
cea
level
measur
therapeut
cycl
ct
scan
perform
review
blind
fashion
everi
week
evalu
clinic
respons
base
recist
version
basi
structur
model
comput
design
design
mutant
cetuximab
mab
mutat
cleavag
region
contain
potenti
recognit
region
contain
vector
pabg
pabl
construct
laboratori
use
express
cetuximab
mutant
recombin
light
heavi
chain
vector
cotransfect
freestyl
cell
invitrogen
instantan
express
variant
mab
antibodi
secret
supernat
purifi
use
hitrap
protein
ff
column
ge
healthcar
first
download
express
file
clinic
file
cancer
type
tcga
http
clinic
file
express
result
obtain
level
tcga
data
basi
median
level
cancer
type
tcga
databas
divid
patient
receiv
cetuximab
monotherapi
bevacizumab
monotherapi
high
high
group
kaplanmei
method
use
estim
pf
os
valu
report
mean
sd
data
analyz
spss
version
spss
inc
student
test
use
comparison
variabl
kaplanmei
surviv
curv
estim
logrank
test
use
assess
differ
surviv
distribut
relat
express
clinic
variabl
analyz
signific
differ
experiment
group
test
twosid
p
p
p
consid
statist
signific
